Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of “Hold” from Analysts

Shares of Roche Holding AG (OTCMKTS:RHHBY) have earned an average recommendation of “Hold” from the eleven analysts that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $51.50.

Several analysts have commented on the stock. Argus upgraded shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Morgan Stanley raised shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price for the company in a report on Friday, April 24th.

Roche Stock Performance

Shares of OTCMKTS RHHBY opened at $53.04 on Friday. Roche has a 52 week low of $37.51 and a 52 week high of $60.85. The business’s 50 day moving average price is $51.29 and its 200 day moving average price is $52.68. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72.

Hedge Funds Weigh In On Roche

A number of institutional investors have recently modified their holdings of RHHBY. Curio Wealth LLC acquired a new position in shares of Roche in the 3rd quarter valued at about $25,000. McIlrath & Eck LLC acquired a new stake in Roche during the first quarter worth about $39,000. Oakworth Capital Inc. raised its position in Roche by 20.8% during the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after acquiring an additional 285 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in Roche during the fourth quarter valued at approximately $192,000. Finally, Douglass Winthrop Advisors LLC acquired a new position in Roche in the third quarter valued at approximately $201,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann?La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.